Coherus Oncology, Inc. (CHRS)
NASDAQ: CHRS · Real-Time Price · USD
1.490
-0.075 (-4.79%)
At close: Nov 6, 2025, 4:00 PM EST
1.370
-0.120 (-8.05%)
Pre-market: Nov 7, 2025, 7:42 AM EST
Coherus Oncology Revenue
Coherus Oncology had revenue of $11.57M in the quarter ending September 30, 2025, a decrease of -83.65%. This brings the company's revenue in the last twelve months to $213.01M, up 21.79% year-over-year. In the year 2024, Coherus Oncology had annual revenue of $266.96M with 3.78% growth.
Revenue (ttm)
$213.01M
Revenue Growth
+21.79%
P/S Ratio
0.81
Revenue / Employee
$934,237
Employees
228
Market Cap
173.18M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 266.96M | 9.72M | 3.78% |
| Dec 31, 2023 | 257.24M | 46.20M | 21.89% |
| Dec 31, 2022 | 211.04M | -115.51M | -35.37% |
| Dec 31, 2021 | 326.55M | -149.27M | -31.37% |
| Dec 31, 2020 | 475.82M | 119.75M | 33.63% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
CHRS News
- 15 hours ago - Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 18 hours ago - Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer - GlobeNewsWire
- 8 days ago - Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025 - GlobeNewsWire
- 15 days ago - Coherus Oncology to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - 4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals - Benzinga
- 5 weeks ago - Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) - GlobeNewsWire
- 5 weeks ago - Coherus Oncology, Inc. (CHRS) Presents at UBS Virtual Oncology Day Transcript - Seeking Alpha
- 5 weeks ago - Coherus Oncology: Five Readouts Or More Possible In 2026 - Seeking Alpha